Author

T. Bivona

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 2 Research Focus:development & morphogenesis· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

R. Okimoto· 2 shared A. B. Molofsky· 1 shared A. Bhattacharyya· 1 shared A. Ghosh· 1 shared A. Heslin· 1 shared A. R. Abate· 1 shared A. Sweet-Cordero· 1 shared A. Tulpule· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

R. Okimoto

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Myeloid-mesenchymal crosstalk drives Arg1-dependent profibrotic metabolism via ornithine in lung fibrosis

P. Yadav, J. Gomez Ortega, P. Dabral, W. Tamaki, C. Chien, K.-C. Chang, N. Biswas, S. Pan, J. Nilsson, X. Yin, A. Bhattacharyya, K. Boostanpour, T. Jujaray, J. Wang, T. Tsukui, , M. Bhattacharya

The paper identifies a myeloid-mesenchymal crosstalk pathway involving Arg1 and ornithine that drives profibrotic metabolism in lung fibrosis.

bioRxiv · Sep 6, 2023Immunology

FET fusion oncoproteins disrupt physiologic DNA repair and create a targetable opportunity for ATR inhibitor therapy

S. Menon, D. Gracilla, M. R. Breese, Y. P. Lin, F. S. Dela Cruz, T. Feinberg, E. De Stanchina, A.-F. Galic, H. Allegakoen, s. perati, N. Wen, A. Heslin, M. Horlbeck, J. S. Weissman, A. Sweet-Cordero, , A. Tulpule

This study shows FET fusion oncoproteins disrupt DNA repair by inhibiting ATM signaling, making ATR inhibitors a potential therapy for FET rearranged cancers.

bioRxiv · Apr 30, 2023 · PreprintCancer Biology

In vivo CRISPRi screen reveals the differential requirement for mitochondrial respiratory chain function between in vivo and in vitro tumor growth

H. Nakaoka, N. Bennett, R. Okimoto, D. Laurent, Y. Sei, T. Bivona, J. ten Hoeve, T. Graeber, K. Nakamura, J. Nakamura

The paper uses CRISPRi to show that mitochondrial respiratory chain genes are critical for in vivo tumor growth but not for metastasis in lung cancer xenografts.

bioRxiv · Oct 3, 2021 · PreprintCancer Biology

Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR mutant lung cancer

S. Nanjo, W. Wu, N. Karachaliou, C. Blakely, J. Suzuki, S. Ali, L. Kerr, V. Olivas, J. Shue, J. Rotow, M. Mayekar, F. Haderk, N. Chatterjee, A. Urisman, Y. Kirichok, , T. Bivona

This study shows that RBM10 deficiency reduces EGFR inhibitor efficacy in EGFR mutant lung cancer by altering Bcl-x splicing and apoptosis, and that co-inhibiting Bcl-xL can overcome this resistance.

bioRxiv · Oct 26, 2020 · PreprintCancer Biology